Immunoglobulin dynamics and infection risk with ofatumumab versus ocrelizumab in multiple sclerosis.

Tešija K, Sredanović M, Zanetti L, Gabelić T, Adamec I, Barun B, Krbot Skorić M, Habek M

Mult Scler Relat Disord. 2026 Jul 04; 113:107373. PMID: 42413316. Abstract